Reclassification of Variants of Uncertain Significance in BRCA1, BRCA2, and PALB2: Implications for Clinical Decision-Making in Breast Cancer
This retrospective study of 6,369 breast cancer patients demonstrates that while the reclassification rate of Variants of Uncertain Significance (VUS) in BRCA1, BRCA2, and PALB2 is low (3%), the process significantly impacts clinical decision-making by resolving uncertainty and guiding therapeutic strategies.